HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PAPD5

[1]  J. Roa,et al.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis , 2016, Oncogene.

[2]  Huan Yang,et al.  MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3. , 2015, Biochemical and biophysical research communications.

[3]  T. Katoh,et al.  Destabilization of microRNAs in human cells by 3′ deadenylation mediated by PARN and CUGBP1 , 2015, Nucleic acids research.

[4]  Hui Zhang,et al.  MicroRNA-21 regulates non-small cell lung cancer cell proliferation by affecting cell apoptosis via COX-19. , 2015, International journal of clinical and experimental medicine.

[5]  W. Zhang,et al.  ErbB2-intronic MicroRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling , 2015, Cell Death and Disease.

[6]  Christian Brueffer,et al.  The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine , 2015, Genome Medicine.

[7]  Joana A. Vidigal,et al.  In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA , 2015, Proceedings of the National Academy of Sciences.

[8]  Wei-Chung Cheng,et al.  YM500v2: a small RNA sequencing (smRNA-seq) database for human cancer miRNome research , 2014, Nucleic Acids Res..

[9]  Y. Shu,et al.  MiR-4728-3p could act as a marker of HER2 status. , 2015, Cancer biomarkers : section A of Disease markers.

[10]  H. Yao,et al.  miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. , 2014, Cancer research.

[11]  B. Nielsen,et al.  miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer , 2014, Front. Oncol..

[12]  Piero Carninci,et al.  PAPD5-mediated 3′ adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease , 2014, Proceedings of the National Academy of Sciences.

[13]  R. Søkilde,et al.  The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction , 2014, PloS one.

[14]  Kang Yang,et al.  MiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth muscle cells. , 2014, Cellular signalling.

[15]  Fen Hu,et al.  microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. , 2014, International journal of clinical and experimental pathology.

[16]  A. Pintzas,et al.  Epigenetic regulation of miR-21 in colorectal cancer , 2014, Epigenetics.

[17]  Tsutomu Suzuki,et al.  Poly(A)-specific ribonuclease mediates 3'-end trimming of Argonaute2-cleaved precursor microRNAs. , 2013, Cell reports.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[19]  C. Thompson,et al.  Long-lived microRNA–Argonaute complexes in quiescent cells can be activated to regulate mitogenic responses , 2012, Proceedings of the National Academy of Sciences.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[21]  Joshua T. Mendell,et al.  A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts , 2012, Nucleic acids research.

[22]  L. Bi,et al.  Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. , 2012, Journal of proteome research.

[23]  S. Wyman,et al.  Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. , 2011, Genome research.

[24]  T. Thum,et al.  Regulation and function of miRNA-21 in health and disease , 2011, RNA biology.

[25]  S. Cirera,et al.  Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers , 2011, BMC biotechnology.

[26]  Chang Gong,et al.  Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.

[27]  Å. Borg,et al.  Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. , 2011, Cancer research.

[28]  Y. Hayashizaki,et al.  A comprehensive survey of 3' animal miRNA modification events and a possible role for 3' adenylation in modulating miRNA targeting effectiveness. , 2010, Genome research.

[29]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Z. Paroo,et al.  Phosphorylation of the Human MicroRNA-Generating Complex Mediates MAPK/Erk Signaling , 2009, Cell.

[31]  Michael T. McManus,et al.  Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion* , 2009, The Journal of Biological Chemistry.

[32]  Maurizio Scaltriti,et al.  A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis , 2009, Molecular and Cellular Biology.

[33]  T. Katoh,et al.  Selective stabilization of mammalian microRNAs by 3' adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. , 2009, Genes & development.

[34]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[35]  Shuji Fujita,et al.  miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. , 2008, Journal of molecular biology.

[36]  Jörg Hackermüller,et al.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.

[37]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[38]  J. Garcia-conde,et al.  p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer , 2006, Clinical Cancer Research.

[39]  J. Lin,et al.  NH 2-terminally Truncated HER-2 / neu Protein : Relationship with Shedding of the Extracellular Domain and with Prognostic Factors in Breast Cancer 1 , 2006 .

[40]  Chien-Hsing Lu,et al.  Mechanisms of Trastuzumab Resistance and Their Clinical Implications , 2005, Annals of the New York Academy of Sciences.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[43]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[44]  M. Campiglio,et al.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Doherty,et al.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.

[46]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.